eikb SHC charges Admore ... 投稿者：Charlesteutend 投稿日：2024/05/20(Mon) 02:16 No.18087537 
Bucx Multigene Testing Proves Useful for Breast and Ovarian Cancer
ISLAMABAD:Prime Minister Nawaz Sharif has approved the appointment of a new project coordinator for the $51-billion China-Pakistan Economic Corridor (CPEC), whil [url=https://www.nbbalance.it]new balance donna[/url] e the Islamabad High Court has granted a stay order against [url=https://www.stanley-cup.com.de]stanley cup[/url] the appointment of the Chief Economist.The premier has approved the summary for the appointment of Asim Saeed as new project director of CPEC besides rehiring Chief Economist Dr Nadeem Javaid and other members of the Planning Commission, said officials of the Planning Ministry.Govt to re-advertise post of CPEC coordinator, extend members?contractsHowever, the Islamabad High Court has already stopped the Chief Economist from working after the Economist Group challenged his appointment on the grounds that the post belongs to the Group and a person from the private sector cannot be hired.The government made the decision to retain the incumbent chief economist after it decided not to return the sole grade-22 position of the Economist Group. It had turned do [url=https://www.nbbalance.es]newbalance[/url] wn a representa Silence Therapeutics plcand Quark Pharmaceuticals, Inc. have announced an expansion of their current strategic technology licensing agreement.In April 2005 the Companies signed an Option and Licence Agreement, which provided Quark with access to Silence Therapeutics'siRNA technology, AtuRNAi.The first outcome of Companies' relationship was the development of the AtuRNAi technolo [url=https://www.nike-dunks.de]nike dunks[/url] gy-based compound RTP801i, which was licensed to Pfizer Inc in 2006 by Quark and is currently in a phase 1 clinical trial in patients with wet age- [url=https://www.nike-dunks.de]nike dunk low[/url] related macular degeneration. Quark's product portfolio includes one additional siRNA molecule with a structure covered by patents licensed from Silence Therapeutics.The expanded agreement provides Quark with op [url=https://www.nbbalance.de]nb[/url] tions to non-exclusive licenses to develop additional molecules against 3 specific targets using Silence Therapeutics' AtuRNAi technology.The terms of the amendment signed will entitle Silence Therapeutics to milestone payments and a royalty on product sales af
|